ALK and non-small cell lung carcinoma: Epidermal growth factor receptor (EGFR) tyrosine kinase Inhibitor (TKI) (gefitinib, erlotinib, afatinib, icotinib, and osimertinib, dacomitinib) and anaplastic lymphoma kinase (ALK) inhibitors (crizotinib, ceritinib, alectinib, brigatinib, and lorlatinib) are used for treating EGFR-mutated or ALK-rearranged non-small-cell lung cancers (NSCLC) patients, respectively [11].